标签归档：vegf

Deoxyshikonin

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Deoxyshikonin  纯度: 99.96%

Deoxyshikonin 从紫草 Lithospermum erythrorhizon 中分离，具有抗肿瘤活性。Deoxyshikonin增加 HMVEC-dLy 中 VEGF-C 和 VEGF-A mRNA 的表达，促进 HIF-1α 和 HIF-1β 亚基相互作用，并与 HIF 特异性 DNA 序列结合。Deoxyshikonin 在体外具有促血管生成作用。Deoxyshikonin 显示出显着的协同抗微生物活性, S. pneumonia (MIC =17μg/mL)，也显示出对 MRSA 的显着抑制活性。

Deoxyshikonin

Deoxyshikonin Chemical Structure

CAS No. : 43043-74-9

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥2696 In-stock
5 mg ￥2550 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Deoxyshikonin 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Antibacterial Compound Library
  • Phenols Library
  • Glutamine Metabolism Compound Library
  • Traditional Chinese Medicine Monomer Library
  • Anti-Breast Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Angiogenesis Related Compound Library
  • Transcription Factor Targeted Library

生物活性

Deoxyshikonin is isolated from Lithospermum erythrorhizon Sieb with antitumor activity. Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF, indicates a prolymphangiogenesis as well as a proangiogenesis effect in vitro[1]. Deoxyshikonin shows significant synergic antimicrobial activity against S. pneumonia (MIC=17 μg/mL), also shows significantly inhibitory activities against MRSA[2].

分子量

272.30

Formula

C16H16O4
CAS 号

43043-74-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 33.33 mg/mL (122.40 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.6724 mL 18.3621 mL 36.7242 mL
5 mM 0.7345 mL 3.6724 mL 7.3448 mL
10 mM 0.3672 mL 1.8362 mL 3.6724 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.18 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.18 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Prangsaengtong O, et al. Enhancement of Lymphangiogenesis In Vitro via the Regulations of HIF-1α Expression and Nuclear Translocation by Deoxyshikonin. Evid Based Complement Alternat Med. 2013;2013:148297.

    [2]. Zhang S, et al. Antibacterial effects of Traditional Chinese Medicine monomers against Streptococcus pneumoniae via inhibiting pneumococcal histidine kinase (VicK). Front Microbiol. 2015 May 20;6:479.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

人血管内皮细胞生长因子（VEGF）ELISA试剂盒BS-0114

发表于由

人血管内皮细胞生长因子（VEGF）ELISA试剂盒

  • 产品型号：BS-0114
  • 简要描述：人血管内皮细胞生长因子（VEGF）ELISA试剂盒金畔生物公司供应：ELISA试剂盒,分光光度计，血清，荧光定量PCR耗材，移液器吸嘴，微量离心管，进口冻存管，细胞培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。
产品咨询在线客服
  • 产品简介

人血管内皮细胞生长因子(VEGF)ELISA试剂盒金畔生物公司供应：ELISA试剂盒,分光光度计，血清，荧光定量PCR耗材，移液器吸嘴，微量离心管，进口冻存管，细胞培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。

人ELISA试剂盒  人ELISAkit 白介素试剂盒 试剂盒代测

货号：BS-0114

中文名称：96T/48T

规格：人血管内皮细胞生长因子(VEGF) ELISA试剂盒

检测种属：人、大小鼠、豚鼠、兔子、猪、犬、牛羊、鸡鸭、猴ELISA试剂盒等种属。

检测范围：
20μg/L -400μg/L
保存条件及有效期：
1、试剂盒保存：2-8℃。
2、有效期：6个月

用途：科研实验，不用于临床诊断。

elisa试剂盒是一种敏感性高、特异性强、重复性好的实验诊断方法，由于其试剂稳定、易保存、操作简便、结果判断较客观等因素，以及既适宜于大规模筛查试验又可以用于少量标本的检测，既可以做定性试验也可以做定量分析等优点，已广泛应用于微生物学、寄生虫学、肿瘤学和细胞因子等领域。

人血管内皮细胞生长因子(VEGF)ELISA试剂盒
ELISA试剂盒的特点：
1、采用全进口原料和抗体-高效、灵敏、特异，严格运用生产标准进行 批量生产;
2、规范包被操作-吸附均匀，吸附性好，空白值低，孔底透明度高;
3、先进的优化方案-重复性高，可靠性强;
4、购买本公司的ELISA试剂盒，免费代测;
5.产品现货充足，发货及时;
6、技术服务：专业，及时，耐心;
7、适用于血浆、血清、组织匀浆液、细胞培养上清液、尿液等多种类型的样本;
8、可检测动物类型丰富：人、猴、大鼠、小鼠、豚鼠、兔、猪、犬、牛、绵羊、鸡 、虾、鱼等;
9、可检测指标齐全：炎症因子、血管生成素、动脉粥样硬化因子、趋化因子、生长 因子基质金属蛋白酶、脂肪因子等等;
10、经济、实惠、可靠，完善、稳定的实验体系，有的科研队伍，先进的实验设备 、准确可靠的实验结果，是您实验合作的选择;

相关试剂盒推荐：

BS-0082人白血病抑制因子(LIF)ELISA试剂盒

BS-0083人瘦素(LEP)ELISA试剂盒

BS-0084人苗条素受体(LR/Ob-R)ELISA试剂盒

BS-0085人层连蛋白/板层素(LN)ELISA试剂盒

BS-0086人白介素9(IL-9)ELISA试剂盒

BS-0087人胃蛋白酶原I(PGI)ELISA试剂盒

BS-0088人血管生成素受体Tie1(ANG-R-Tie1)ELISA试剂盒

BS-0089人转化生长因子β1(TGF-β1)ELISA试剂盒

BS-0090人转化生长因子α(TGF-α)ELISA试剂盒

BS-0091人基质细胞衍生因子1β(SDF-1β/CXCL12)ELISA试剂盒

BS-0092人干细胞因子受体(SCFR)ELISA试剂盒

BS-0093人干细胞因子/肥大细胞生长因子(SCF/MGF)ELISA试剂盒

BS-0096人正常T细胞表达和分泌因子(RANTES/CCL5)ELISA试剂盒

BS-0097人P选择素(P-Selectin/CD62P)ELISA试剂盒

BS-0098人胎盘生长因子(PLGF)ELISA试剂盒

BS-0099人血血小板衍生生长因子AB(PDGF-AB)ELISA试剂盒

BS-0100人血血小板衍生生长因子可溶性受体α(PDGFsR-α)ELISA试剂盒

BS-0101人抑瘤素M(OSM)ELISA试剂盒

BS-0102人神经营养因子4(NT-4)ELISA试剂盒

BS-0103人神经营养因子3(NT-3)ELISA试剂盒

BS-0104人胃蛋白酶原II(PGII)ELISA试剂盒

BS-0105人基质金属蛋白酶8/中性粒细胞胶原酶(MMP-8)ELISA试剂盒

BS-0106人基质金属蛋白酶7(MMP-7)ELISA试剂盒

BS-0107人基质金属蛋白酶3(MMP-3)ELISA试剂盒

BS-0108人血管内皮细胞生长因子受体3(VEGFR-3)ELISA试剂盒

BS-0109人血管内皮细胞生长因子受体2(VEGFR-2)ELISA试剂盒

BS-0110人血管内皮细胞生长因子受体1(VEGFR-1)ELISA试剂盒

BS-0111人血管内皮细胞生长因子D(VEGF-D)ELISA试剂盒

BS-0112人血管内皮细胞生长因子C(VEGF-C)ELISA试剂盒

BS-0113人血管内皮细胞生长因子B(VEGF-B)ELISA试剂盒

产品用途：可用于科研实验,不用于临床治疗！

Bevacizumab(Synonyms: 贝伐珠单抗; Anti-Human VEGF, Humanized Antibody)

发表于由

Bevacizumab (Synonyms: 贝伐珠单抗; Anti-Human VEGF, Humanized Antibody) 纯度: 98.10%

Bevacizumab 是一种人源化的 IgG1 单克隆抗体，高亲和力且特异性地与所有 VEGF-A 结合。

Bevacizumab(Synonyms: 贝伐珠单抗; Anti-Human VEGF, Humanized Antibody)

Bevacizumab Chemical Structure

CAS No. : 216974-75-3

规格 价格 是否有货 数量
1 mg ￥1600 In-stock
5 mg ￥5500 In-stock
25 mg 询价
50 mg 询价

* Please select Quantity before adding items.

生物活性

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

IC50 & Target

VEGF[1]
体外研究
(In Vitro)

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

149 kDa(Average)

CAS 号

216974-75-3
中文名称

贝伐珠单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.

    [2]. Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17.

    [3]. Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.
Cell Assay
[2]

Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2][3]

Rats[2]
After modeling, ninety rats are randomly divided into five groups (eighteen rats per group) and receive a subconjunctival injection with 0.05 mL per rat of (1) 0.9% NaCl, (2) solvent, (3) 25 mg/mL Bevacizumab and (4) 25 mg/mL FD006 in the superior temporal conjunctiva on the day after modeling. All chemical burns and treatments are performed by one investigator. The operator is blinded to the treatment group from which each cornea is derived. At postoperative days 3, 7, 14, 21 and 28, the eyes are harvested for further studies after the rats are sacrificed.
Mice[3]
Five-week-old Balb/cAnNCrlBR athymic (nu+/nu+) mice are injected into the fourth mammary fat pad with MDA-MB-468 cells (107 cells per mice) resuspended in 200 μL of Matrigel. Seven days after the tumor cell injection, tumor-bearing mice are randomly assigned (n=10 per group) to receive the following: NVP-LDE225 20 mg/kg per os every day for 4 weeks; Bevacizumab 5 mg/kg intravenously (i.v.), twice a week for 4 weeks. Tumor diameter is assessed with a vernier caliper, and tumor volume (cm3) is measured.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.

    [2]. Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17.

    [3]. Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.

Ramucirumab(Synonyms: 雷莫芦单抗)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ramucirumab (Synonyms: 雷莫芦单抗) 纯度: 99.40%

Ramucirumab 是人 VEGFR-2 拮抗剂，具有抗实体瘤作用。Ramucirumab 是一种人源化单克隆抗体，可与 VEGFR-2 结合，阻止 VEGFR 配体 VEGF-A，VEGF-C 和 VEGF-D 结合。

Ramucirumab(Synonyms: 雷莫芦单抗)

Ramucirumab Chemical Structure

CAS No. : 947687-13-0

规格 价格 是否有货 数量
1 mg ￥4000 In-stock
5 mg ￥9900 In-stock
25 mg 询价
50 mg 询价

* Please select Quantity before adding items.

生物活性

Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors[1]. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D[2].

IC50 & Target[1][2]

VEGFR-2

 

Clinical Trial

分子量

143609.63

Formula

C6374H9864N1692O1996S46
CAS 号

947687-13-0
中文名称

雷莫芦单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.

    [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(Z)-Guggulsterone

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

(Z)-Guggulsterone  纯度: 98.43%

Z-guggulsterone 是印度阿育吠陀药用植物 Commiphora mukul 的成分，通过引起细胞凋亡 (apoptosis) 来抑制人前列腺癌细胞的生长。 Z-guggulsterone 通过抑制 VEGF-VEGF-R2-Akt 信号传导轴来抑制血管生成。

(Z)-Guggulsterone

(Z)-Guggulsterone Chemical Structure

CAS No. : 39025-23-5

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥2200 In-stock
5 mg ￥1300 In-stock
10 mg ￥2000 In-stock
25 mg ￥4000 In-stock
50 mg ￥6200 In-stock
100 mg ￥8800 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

(Z)-Guggulsterone 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Protein Tyrosine Kinase Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Lipid Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis[1].

IC50 & Target[1]

VEGF-R2

 

Akt

 

体外研究
(In Vitro)

Z-guggulsterone (10, 20 μM; 24 or 48 hours) causes a decrease in the level of VEGF-R2 protein in HUVEC[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Vascular endothelial growth factor (VEGF)
Concentration: 10, 20 μM
Incubation Time: 24 or 48 hours
Result: Caused a decrease in the level of VEGF-R2 protein in HUVEC.

体内研究
(In Vivo)

Z-guggulsterone (oral; 1 mg; 5 times/week) results in a statistically significantly decrease in tumor volume and wet tumor weight[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male nude mice (5–6 weeks old) s.c. implanted with DU145 cell-containing Matrigel plugs
Dosage: 1 mg
Administration: Oral; 5 times/week
Result: Resulted in a statistically significantly decrease in tumor volume and wet tumor weight.

分子量

312.45

Formula

C21H28O2
CAS 号

39025-23-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 10 mg/mL (32.01 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.2005 mL 16.0026 mL 32.0051 mL
5 mM 0.6401 mL 3.2005 mL 6.4010 mL
10 mM 0.3201 mL 1.6003 mL 3.2005 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2 mg/mL (6.40 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (6.40 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1 mg/mL (3.20 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (3.20 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Xiao D, et al. z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol Cancer Ther. 2008 Jan;7(1):171-80.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Bevacizumab (PBS)(Synonyms: Anti-Human VEGF, Humanized Antibody (PBS))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Bevacizumab (PBS) (Synonyms: Anti-Human VEGF, Humanized Antibody (PBS)) 纯度: 98.94%

Bevacizumab 作为人源化血管内皮生长因子（VEGF）抗体，是一种高效的单克隆抗体。Bevacizumab 可用于癌症研究。

Bevacizumab (PBS)(Synonyms: Anti-Human VEGF, Humanized Antibody (PBS))

Bevacizumab (PBS) Chemical Structure

CAS No. : 216974-75-3

规格 价格 是否有货 数量
5 mg ￥5500 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

生物活性

Bevacizumab, as a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used for the research of cancer[1][2].

体外研究
(In Vitro)

Bevacizumab-loaded hydrogel results in significant tumor reduction. Bevacizumab is taken up by other organs, including the heart, lung, and spleen. Bevacizumab accumulates higher within tumors via Bevacizumab-loaded hydrogel administration from 14 days onward as compared to the solution formulation. Bevacizumab (I.v.) solution, a typical drug clearance profile is observed where the antibody is cleared from the circulatory system with a half-life of ~4~5 days. The Bevacizumab-loaded hydrogel and the weekly administration of Bevacizumab solution inhibits tumor growth/metastasis in the peritoneal cavity, while one-time i.v. injection of Bevacizumab solution does not provide any therapeutic effect, leading to extensive tumor metastasis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

CAS 号

216974-75-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-80°C
参考文献

  • [1]. Liu W, et al. Effect of Avastin on the migration and invasion of pterygium fibroblasts. Eye Sci. 2014;29(4):214-218.

    [2]. Lee AL, et al. Injectable biodegradable hydrogels from vitamin D-functionalized polycarbonates for the delivery of avastin with enhanced therapeutic efficiency against metastatic colorectal cancer. Biomacromolecules. 2015;16(2):465-475.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务